Exploring Nanoemulsion for Liver Cancer Therapy

(E-pub Ahead of Print)

Author(s): Vaseem Ansari*, Usama Ahmad, Tanmay Upadhyay, Nazneen Sultana, Juber Akhtar

Journal Name: Current Cancer Therapy Reviews

Become EABM
Become Reviewer

Abstract:

Cancer is a leading cause of mortality worldwide, accounting for 8.8 million deaths in 2015. Amongst these at least 0.78 million people have died of liver cancer alone. The recognized risk factors for liver cancer include chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection, exposure to dietary aflatoxin, fatty liver disease, alcohol-induced cirrhosis, obesity, smoking, diabetes, and iron overload. Treatment plan for early diagnosed patients include radiation therapy, tumour ablation, surgery, immunotherapy and chemotherapy. Some sort of drug delivery vehicles has to be used when the treatment plan is targeted chemotherapy. Nanoemulsions are a class of biphasic liquid dosage form which are mixtures of oil and water stabilized by a surfactant. They are either transparent or bluish in hue and serve as a wonderful carrier system for chemotherapeutic drugs. These vehicles have particle size in the range of 20-200nm allowing them to be delivered successfully in the deepest of tissues. Recent publications on nanoemulsions reveal their acceptance and a popular choice for delivering both synthetic and herbal drugs to liver. This work focuses on some anti-cancer agents which have utilized advantages of nanoemulsion for liver cancer therapy.

Keywords: Nanoemulsion, Liver Cancer, Hepatocellular Carcinoma, Drug Delivery

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1573394716666200302123336

Article Metrics

PDF: 1